The purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.
Age 18-65 years at consent
Body weight 40-100 kg at screening
Written informed consent obtained
Newly diagnosed pulmonary TB, rifampicin- and isoniazid-sensitive
Prior TB within 3 years, >1 prior episode, or anti-TB treatment within 60 days
Extrapulmonary TB (except non-significant pleural/lymph node disease)
Clinically significant comorbidities or substance abuse impacting safety/compliance
Pregnant or breastfeeding
Gates Medical Research Institute
Lead sponsor
IQVIA RDS Inc.
Collaborator